SLAS2026 Exhibitor Tutorials
Exhibitor Tutorials offer a powerful platform for sponsors to engage attendees with detailed product information and technical programming.
Key:
Complete
Next
Failed
Available
Locked
ANALYTIK JENA - CyBio FeliX as Your Excellent Source of Protein – Now Including the Tough Ones. Automated purification from antibodies to membrane proteins in their native lipid environment.
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Purifying proteins shouldn’t be a bottleneck. CyBio FeliX offers a comprehensive range of automated workflows—covering antibodies, tagged proteins, and more—delivering speed, reproducibility, and scalability with protocols designed for flexibility and ease of use.
We will showcase these proven solutions and how they simplify routine purification tasks. Building on this foundation, we introduce a breakthrough for one of the toughest targets: membrane proteins. In close partnership with Cube Biotech, we integrate NativeMP™ copolymer technology to maintain membrane proteins in their native lipid environment, preserving structural integrity and functionality.
Join us to discover how automation, strong collaboration, and innovative chemistry converge to overcome complex purification challenges and unlock new possibilities for structural biology and drug discovery.
HIGHRES BIOSOLUTIONS - Orchestration and Data Automation for the Intelligent Lab
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Modern laboratories face a critical challenge: scientists are drowning in data management managing research samples across multiple instruments and software systems from different vendors, instead of driving discovery. Benchling and Cenevo will join HighRes in highlighting AI-powered lab productivity solutions that address the root causes: reducing human error, accelerating workflows, and establishing governance that scales.
This tutorial with our software partners demonstrates how intelligent automation transforms lab operations from data bottleneck to strategic advantage.
Attendees Will Learn:
- How to eliminate manual errors while accelerating time-to-insight
- Strategies for building AI-ready data infrastructure without ripping and replacing existing systems
- Real-world automation workflows that deliver immediate ROI
- Practical approaches to data governance that enable, rather than restrict, scientific innovation
This Exhibitor Tutorial will empower scientists and demonstrate how leading labs are breaking free from clunky spreadsheets and manual processes, creating the clean, connected data foundation that powers next-generation AI strategies for lab orchestration and operations.
TECAN TRADING AG - Agentic AI in the Lab: Smarter Workflows, Higher Throughput
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Agentic AI is transforming lab productivity - but what does that look like in practice? Join us for an engaging session where innovators from industry and academia will share their firsthand experience with Agentic AI in the lab.
See how autonomous AI agents can be used responsibly to automate key steps in life science research, uncover hidden patterns limiting lab throughput and enable scalability. The presented use cases will cover the scientific and operational impact, as well as the software and hardware foundations required to make them work.
Whether you’re in pharma, biotech, or clinical labs, you’ll leave with concrete examples and insights to help you navigate your own AI journey.
The session will feature concise presentations followed by an open, interactive discussion—bring your questions and ideas!
A buffet lunch will be served in the meeting room.
CURIOX BIOSYSTEMS - Replace Your Centrifuge with a Pipette Robot: Centrifuge-Free Automation with C-FREE™ Pluto CODE
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Automation teams are eliminating the centrifuge as the last manual bottleneck in cell processing. This tutorial introduces C-FREE™ Pluto CODE — the software framework that enables any liquid handler to perform gentle, reproducible cell washing without centrifugation.
Through data and insights from AstraZeneca and ETH Zurich, attendees will see how a pipette robot can deliver SOP-equivalent performance in 96-well format, using programmable wash physics rather than hardware spin-force.
The session will demonstrate how Pluto CODE standardizes washing, reduces variability, and accelerates assay transfer across sites.
Learning Objectives:
By the end of this session, participants will be able to:
1. Understand the practical implications of a centrifuge-free wash method implemented through Pluto CODE on common liquid-handling platforms.
2. Recognize the significance of peer-generated validation from AstraZeneca and ETH Zurich demonstrating reproducibility, gentle handling, and workflow reliability.
3. Appreciate how software-defined washing can mirror SOP intent, reduce operator variability, and simplify assay transfer across automation environments.
4. Envision how centrifuge-free cell processing scales from 96-well automation today and 384-well format, enabling new classes of cell-based assays.
OPENTRONS - The New Throughput: How Adaptive Automation Is Accelerating DNA Synthesis, Molecular Diagnostics and Drug Discovery
Open to view video. | Closed captions available
Open to view video. | Closed captions available
“High throughput” used to mean monolithic, closed automation systems: powerful but rigid, designed for fixed workflows and consistent sample volumes. But today’s scientific landscape looks very different. Advances in AI, explosive computational capacity, faster and more economical chemistries, and data-rich community initiatives like biobanks are not only increasing the demand for throughput but also redefining it. These forces are driving the need for a new kind of automation: systems that are not just fast, but flexible, modular, and adaptive, capable of evolving with new methods, new assays, and new scales of discovery.
This talk explores the new throughput: automation that enables labs to scale dynamically, integrate diverse workflows, and accelerate innovation without sacrificing precision or usability.
We’ll share three use cases from teams pushing the boundaries of scale and adaptability in very different ways:
Madeline Wolf, Instance Bio – leveraging AI-driven, massively parallel DNA synthesis to generate unbounded DNA pools at unprecedented speed, scale, and size.
Arun Timmaraju, Interpace Diagnostics – applying scalable automation to accelerate molecular diagnostics workflows.
Hamza Sahil, Pfizer – demonstrating how an automated Oxford Nanopore workflow delivers rapid, scalable plasmid and cell line sequencing, with major gains in speed and efficiency.
Join us to see how advances in AI, computation, chemistry, and collaboration are converging to define the new throughput, one built not just for speed, but for agility, precision, and discovery.
REVVITY HEALTH SCIENCES - High-content imaging strategies for Microphysiological Systems (MPS)
Open to view video. | Closed captions available
Open to view video. | Closed captions available
The first talk, “Scaling-up Complex in vitro Models using Automation-Ready Microphysiological Systems (MPS)” will focus on the integration of AIM Biotech’s MPS models into automated lab infrastructure. As regulators embrace New Approach Methodologies (NAMs), 3D in vitro models are becoming an important part of modern discovery workflows. AIM Biotech’s automation-ready microphysiological systems (MPS) make it straightforward for researchers to generate these models at scale without overhauling existing lab processes. Designed to align with standard lab formats, AIM's idenTx and organiX platforms integrate seamlessly with a wide range of automated tools, from benchtop liquid handlers to advanced automated high-content imagers. This session will showcase how AIM's platforms enable automation and scalability, with a focus on examples from vascular biology.
The second talk, "High Content Imaging in Complex In Vitro Models", will discuss the application of advanced High Content Imaging technologies in characterizing the biological structure and function of CIVM, with particular attention to 3D imaging and analysis within complex spheroids, organoids, and chip-based platforms. Complex in vitro models (CIVM), including three dimensional (3D) tissues and microphysiological systems (MPS), are increasingly incorporated into drug discovery to enhance the assessment of safety, efficacy, and ADME properties. The FDA’s roadmap for human relevant in vitro technologies emphasizes the adoption of new approach methodologies (NAMs) to strengthen the predictive value of preclinical studies and to advance 3Rs objectives.
In the third talk, “Accelerating Discovery with Revvity High-Content Screening Technologies” we will showcase how Revvity’s HCS technologies help bridge the gap between in vitro research and human biology through advanced imaging of complex 3D cell models and live-cell systems. Learn about improved hardware, such as high-quantum efficiency cameras, autofocus enhancements, and hypoxia control. The tutorial will include demonstrations of Phenologic.AI, featuring AI-powered brightfield segmentation and automated cell cycle classification that simplifies analysis while delivering deeper single-cell insights. Attendees will leave with insights on how to accelerate their research timelines and generate more biologically relevant data.
For research use only. Not for use in diagnostic procedures.
GENEDATA AG - Cutting Days from the DMTA Cycle with Intelligent Data Workflows
Open to view video. | Closed captions available
Open to view video. | Closed captions available
The DMTA cycle is central to drug discovery, yet data handling and analysis remain major sources of delay even as wet‑lab automation advances. This tutorial highlights how intelligent data workflows can eliminate these bottlenecks and significantly accelerate Drug discovery projects. We will show how Genedata Screener accelerates the DMTA cycle through vendor‑agnostic integrations, automated data capture, real‑time monitoring, and standardized reporting. AI‑driven capabilities (including automated curve classification, SPR analysis, and QC assessment) further reduce manual workload and ensure rapid, high‑quality insights at scale. Finally, we introduce our roadmap for Assay Cascade Management, extending these efficiencies across full discovery workflows. Together, these innovations demonstrate how automation and smart analytics can remove days from DMTA iterations and increase overall R&D productivity.
HAMILTON - Revolution in Action: User-Driven Software for Cloud-Powered Integration
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Hamilton Robotics continues to deliver industry-leading automated liquid handling systems while expanding capabilities to enable fully integrated automation solutions. In this session, Dhireshan Gadiagellan will spotlight Revolution, a robust and extensible lab automation software platform originally developed by UK Robotics with a user-first design philosophy and share its transformative roadmap. The next generation of Revolution introduces a cloud-deployed architecture that combines a dynamic scheduler, labware storage manager, and AI coding assistant with Python-powered customization. Featuring an intuitive UI and 3D digital twin visualization, Revolution complements Hamilton’s proven hardware performance with the flexibility to integrate virtually any device - —empowering customers to build and scale automation systems with confidence and control.
EVOTEC - Beyond Traditional Screening: Integrating AI/ML with Biophysical and Label Free Approaches for Rapid Hit Identification
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Early drug discovery remains a critical step in the development of new medicines, and AI/ML-supported workflows are becoming increasingly important across all stages—from hit identification (Hit ID) to lead optimization. In this presentation, we will demonstrate how newly implemented workflows accelerate the identification of early-stage hits, serving as seeds for preclinical development candidates.
To streamline the process while maintaining efficiency, we have introduced innovative hit-finding strategies at Evotec. These approaches combine experimental methods that generate large datasets with AI/ML models to facilitate the identification of small-molecule hits. Specifically, our optimized hit selection and iterative screening strategies enable faster progression toward validated hit series. When integrated with advanced experimental workflows using biophysical and other label-free readouts, these methods push beyond the traditional boundaries of hit discovery.
We will illustrate these concepts with real-world examples, including projects utilizing surface plasmon resonance (SPR), mass spectrometry, and other technologies. Additionally, we will highlight Enricture, our recently introduced product that provides a practical, integrated solution for rapid ligandability assessment and Hit ID by coupling affinity selection–mass spectrometry (ASMS) with AI/ML-based hit enrichment. These case studies underscore the power of our strategy to efficiently identify hits within lead-like small-molecule space.
CELLTRIO - Advancing Adherent and Suspension Cell Culture: Celltrio’s Modular Automation for Modern Labs
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Coffee, tea, water, and light snacks will be available.
In this exhibitor tutorial, Celltrio introduces next-generation automation that accelerates adherent and suspension cell culture workflows. As teams face increasing pressure to scale with greater reproducibility, tighter process control, and reduced manual labor, Celltrio demonstrates how full-workflow automation enables reliable, scalable growth for modern cell and gene therapy programs.
Attendees will gain actionable insights into modernizing cell-culture operations using Celltrio’s modular, future-ready automation solutions. The session will highlight how emerging robotic techniques, intelligent scheduling, and integrated environmental controls unify complex processes and deliver consistent, scalable results.
The session will include:
• Celltrio’s end-to-end solutions and customer testimonials for T-flask, TripleFlask™, and HYPERFlask® automation, including plate and conical tube handling, cell counting, incubation, imaging, centrifugation, and cryogenic storage.
• Automated handling of TubeSpin® and Erlenmeyer flask labware, featuring shaking automation, novel gripper designs, geometry-adaptive carriers, and compliant robotic manipulation.
BENCHLING - End-to-end automated workflows for AI-first R&D
Open to view video. | Closed captions available
Open to view video. | Closed captions available
As R&D organizations scale, fragmented tools and disconnected data limit throughput and block the path to automation and AI. In this session, learn how Benchling’s unified platform brings together experiment management and scientific data intelligence to streamline complex workflows, preserve data context, and unlock higher levels of automation. We’ll showcase innovations like Automation Designer and flexible/no-code options that empower scientists and engineers to build end-to-end automated workflows. See how a unified foundation can increase throughput, improve data quality, and prepare your organization for the next wave of intelligent, data-driven discovery.
BRUKER - Tackling new challenges in automated biophysical characterization: from high-throughput hit screening, to bioparticle characterization, to kinetics directly on cells.
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Tackling new challenges in automated biophysical characterization: from high-throughput hit screening, to bioparticle characterization, to kinetics directly on cells.
Lab automation technologies are transforming biologics development by streamlining the selection and optimization of candidates. However, the complexity of biologics—often involving intricate structures and binding interactions—presents challenges in optimizing pharmacokinetics, efficacy, and safety.
In this tutorial, we will not only highlight three advanced automated biophysical tools, but also showcase the all-new iNTA technology for the first time.
You will learn more about: high-throughput, multiplexing Surface Plasmon Resonance (SPR) for rapid candidate identification and detailed lead development; switchSENSE® for analyzing avidity effects, multispecific binders, and protein conformational changes; single-cell Interaction Cytometry for real-time kinetic measurements directly on cells to assess native binding properties. And you will be among the first to learn about interferometric Nanoparticle Tracking Analysis (iNTA) – the next-generation technique in the field of bioparticle characterization.
These tools offer comprehensive profiling to accelerate biologics development by identifying lead candidates with optimal biophysical characteristics and are also applicable to other therapeutic modalities like small molecules.
THERMO FISHER - Compliant Throughput at Scale: Momentum Workflow Scheduling Software in regulated workflows
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Researchers in drug discovery can accelerate preclinical and clinical testing by integrating Thermo Scientific™ Momentum™ Workflow Scheduling Software for lab automation. Momentum enhances productivity, shortens drug development cycles, speeds up regulatory approvals, and improves patient outcomes. By utilizing automated workflows, researchers can standardize processes, reduce human error, and ensure data consistency. This is crucial in regulated environments adhering to Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). Attendees will learn how Momentum enables compliant, efficient lab operations.
HIGHRES BIOSOLUTIONS - Seamless Automation from Sample Management to Screening
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Join us for an interactive tutorial exploring proven strategies for automating sample management workflows in life sciences laboratories. This session features a collaborative presentation between HighRes and (1) Merck who will share their firsthand experience implementing an automated sample management solution, (2) Pfizer, who will highlight their automated screening system, and (3) Enveda, who will share their high-throughput screening operations, highlighting a biologist-driven automation approach that emphasizes simplicity, accessibility, and efficient workflows.
In this educational session, attendees will gain insights into:
- Key considerations when evaluating sample management automation for your laboratory
- Real-world challenges encountered during implementation and how they were addressed
- Best practices derived from successful deployments across global life sciences organizations
- Practical approaches to maximizing value from automated sample management and high throughput screening systems
- The partnership dynamics that enable successful technology adoption
Merck, Pfizer, and Enveda will provide an honest perspective on their journeys, including both the benefits realized and the critical factors they considered when selecting and implementing their solution. This balanced, educational dialogue is designed to help attendees make informed decisions about their own lab automation strategies.
Whether you're currently exploring automation options or looking to optimize existing workflows, this tutorial offers valuable takeaways from those who have successfully navigated the path from manual to automated sample management and high-throughput screening.
AZENTA LIFE SCIENCES - Transforming Drug Discovery: How Merck is Scaling End-to-End Automation within Regulated BioAnalytics
Open to view video. | Closed captions available
Open to view video. | Closed captions available
In Merck’s high-throughput bioanalytical laboratories, a strategic transformation has been underway. In this environment that demands reliability, reproducibility, compliance, and risk mitigation, there is little to no room for manual, repetitive, and labor-intensive processes for sample storage and retrieval that can introduce challenges to operational efficiency and data quality. The only solution is end-to-end automation to scale bioanalytical capacity without a proportional increase in headcount, while supporting the growing clinical pipeline.
Join us for this lunchtime session as Chris Napolitano, Associate Director/Group Lead, Regulated Bioanalytical Sample Management, and Gunnar Jackson, Senior Automation Specialist from Merck, as they share the details of this transformational journey. You’ll hear about the strategic transition of the Merck Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics (PDMB) laboratory from a manually managed freezer farm to a fully integrated, high-density automated sample storage and retrieval system to support escalating Phase I and II clinical trials.
Insights to be shared include:
Efficiencies related to throughput and resource allocation: Learn how the automated system improved testing throughput and recaptured scientists’ time by eliminating time-consuming manual sample logistics.
Improved reproducibility and data quality: Hear how the system ensures reproducibility by standardizing handling and has drastically minimized test result variance.
Ensuring compliance and risk mitigation: Gain insights about the critical role of thermal stability supported by multiple levels of redundancy and the software that supports full audit trails, strengthening the sample chain of custody.
Reduced footprint AND increased storage capacity: Learn how this high-density automated storage capability coupled with high-quality automation-ready consumables is the “master facilitator” for Merck’s lab of the future, consolidating sample inventory and significantly reducing laboratory floor space required.
Lessons learned: Every transformation brings significant learning opportunities and requires critical change management. Hear about the lessons learned during Merck’s journey to end-to-end automation.
TECAN TRADING AG - Labwerx Custom Solutions – From Idea To Impact Faster
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Lab automation moves beyond isolated instruments—but what does true end-to-end execution look like in real labs? Join Labwerx for an engaging tutorial showcasing how leading teams in academia and industry are building scalable automation systems that connect complex workflows across experimentation, processing, and analysis—improving throughput, reproducibility, and traceability along the way.
You’ll hear first from the Wyss Institute on the automation frontier in 3D organoids and bioengineered neural tissues, where robotics and AI converge to help plan, execute, and analyze experiments with minimal human intervention. This approach aims to accelerate discovery by increasing efficiency and consistency today, while enabling scalable, intelligent experimentation that could advance personalized neuroscience and precision medicine in the long term.
Next, Regeneron will share “islands of automation” purification and filtration case studies, including high-throughput micro-scale purification benchmarking against lab-scale systems, automated robocolumn integrity checks, and the practical challenges of integrating purification steps with downstream analytics—especially when limited material volumes constrain analytical testing.
Finally, Nevesco/Merck will present how they connect precision liquid handling with robotic platforms, automated logistics, storage, and digital orchestration to enable end-to-end workflows supporting CMC development, from drug substance and drug product through analytics and QC. Real examples will illustrate how minimizing manual touchpoints while preserving full traceability and reproducibility can accelerate CMC processes and improve operational efficiency.
The tutorial will feature concise presentations followed by an open, interactive discussion—bring your questions and ideas.
REVVITY HEALTH SCIENCES - How to identify and profile proximity-inducing drugs in the cellular context? - A practical approach
Open to view video. | Closed captions available
Open to view video. | Closed captions available
While classical small molecule drugs modulate their target protein's activity, proximity-inducing drugs (""proxidrugs"") modulate their target protein's interactome. As an example of such, molecular degraders induce proximity between a target protein and an E3-ligase leading to proteasomal degradation of the target, a mechanism termed targeted protein degradation (TPD). For proxidrugs to fulfil their promise and overcome major hurdles of classical drugs, they require fit-for-purpose discovery assays enabling their reliable and specific identification, and comprehensive profiling.
This Tutorial will introduce different methods for characterizing proxidrugs in in the cellular context, including immunoassays as a targeted and highly specific format, and the Cell Painting Assay for unbiased profiling of proxidrugs-induced morphological changes. We will share experience on practical implementation of assays and workflows, discuss pitfalls, and highlight paths towards efficient interpretation of results.
For Research Use Only. Not for use in diagnostic procedures.
MOLECULAR DEVICES - Connecting High-Throughput Organoid Workflows to Actionable Results Through AI-Driven Automated Cell Culture and Endpoint Analysis
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Drug development pipelines face high attrition rates, often due to the limited predictive power of traditional 2D cell models. Organoid technologies have emerged as a transformative solution, offering physiologically relevant structures and improved predictivity for drug response. However, scaling organoid culture and performing complex assays remain technical challenges that limit adoption in early-stage screening.
To address these challenges, we developed CellXpress.ai™, an AI-driven automated cell culture system that connects high-throughput organoid workflows to actionable results. This integrated platform automates organoid generation, maintenance, and assay execution using advanced robotics and machine-learning-driven process control. The system combines automated liquid handling, imaging, and incubation with intelligent scheduling and decision-making, enabling dynamic interventions such as passaging, assay initiation, and troubleshooting.
For endpoint analysis, HCS.ai and IN carta deliver advanced imaging and high-content analysis capabilities. These tools enable automated segmentation, phenotypic profiling, and extraction of functional metrics from complex 3D organoid models. Together, they provide deep insights into morphology, viability, and phenotypic changes—turning raw imaging data into actionable results.
We will showcase real-world examples of these connected workflows applied to iPSC-derived models, brain organoids, and patient-derived tumour organoids. These case studies demonstrate how automation and intelligent imaging improve reproducibility, reduce variability, and accelerate decision-making—bridging biology and technology for next-generation drug discovery.
GENEDATA AG - High Content Screening with Genedata Screener
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Image-based assays offer potentially deeper insights about candidate molecules, but their analyses can create a bottleneck, particularly when performed at higher throughput in the drug discovery process. In this tutorial, we will show how to tackle such multiparametric analyses using Genedata Screener, an enterprise platform for assay data analysis and management. Using a deep learning-based analysis platform fully integrated with downstream analytics to streamline high-content screening analysis, Genedata Screener is automating the entire workflow, from instrument-agnostic data loading to automated reporting.
HAMILTON - Enhancing Human Immune Profiling and Research Through Automated NGS Library Preparation on the Hamilton NGS STAR Assay Ready Workstation (ARW)
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Peter Wittig from the Allen Institute for Immunology will discuss how automating 10x Genomics GEM-X gene expression and spatial transcriptomic library preparation workflows on the Hamilton NGS STAR Assay Ready Workstation (ARW) has enabled scalable, high-throughput, and reproducible data generation for comprehensive human immune system studies.
ABCAM - SureFire and SimpleStep ELISA: High sensitivity screening platforms powered by recombinant antibody technology
Open to view video. | Closed captions available
Open to view video. | Closed captions available
In this talk, we’ll delve into the advantages of SimpleStep® ELISA technology, which combines the specificity of recombinant antibodies with the CaptSure immobilization technology. We’ll highlight innovation in high-throughput immunoassays, with a particular focus on SureFire® – the pharmaceutical industry’s go-to platform for high-throughput screening in drug discovery research – as well as a new 384-well format of SimpleStep ELISA. Finally, we’ll examine how our immunoassays effectively solve specific customer challenges, enhancing research efficiency and precision within the field
CUBE BIOTECH - Automating Membrane Protein Drug Discovery: Integrated Platforms from Target to Functional Data
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Membrane proteins remain one of the most challenging target classes in drug discovery, demanding workflows that maintain native structure while enabling automated, reproducible data generation. Cube Biotech has developed a miniaturized, automation-ready screening architecture that supports membrane protein discovery across multiple scales - from low-volume, high-throughput assays to more detailed functional and affinity-based measurements.
This session will highlight how integrated automation strategies and stabilized native membrane protein preparations can unlock scalable discovery workflows and empower downstream partners to generate high-quality functional data rapidly and consistently.
Agenda:
1. Automating Complex Biology: Workflow Design for Membrane Protein Drug Discovery
Cube Biotech, Jan Kubicek
2. AI-Enabled Discovery Workflows for Functional Membrane Protein Targeting
Orogen Therapeutics, Artem Evdokimov
3. Hot diabetes GPCR targets enabled for HTS Affinity Selection Mass Spectrometry
Momentum Bioscience, Can Ozbal
4. Panel Discussion: The Future of Automated Membrane Protein Drug Discovery
LABMAN - Choosing an automation partner - the success story of Alexion, AstraZeneca and Labman
Open to view video. | Closed captions available
Open to view video. | Closed captions available
This vendor‑hosted tutorial presents the early stages of a strategic partnership between Labman and its customers, AstraZeneca and Alexion, to establish foundational chemistry automation labs across multiple sites. Short talks from AZ and Alexion will describe the partnership model, initial design and build activities, and practical lessons learned while establishing these independent, interoperable lab environments. The session will close with a moderated roundtable to surface operational insights and next steps. Attendees will gain a practical view of how vendor–customer collaboration can accelerate deployment of site‑level automation and set the groundwork for future cross‑site capability sharing
ARACELI BIOSCIENCES- uHT Ultra High Throughput Screening Using High-Content Imaging for 3D Growth Analysis
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Virneliz Fernández Vega1, Claudia McCown1, Matthew Boisvert1 , Luis M. Ortiz-Jordan1 , Louis Scampavia1, Timothy P Spicer1
1. Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, FL, USA.
2. Araceli Biosciences, Inc., Tigard, OR, USA
Advances in cancer research and drug discovery have improved significantly with the application of three-dimensional (3D) cellular disease models for high throughput screening (HTS) to better capture physiologically relevant biology mimicking the complexity of in vivo tumors. However, adoption of 3D models in high-throughput screening has been constrained by imaging throughput, data complexity, and the difficulty of scaling quantitative measurements across dense microplate formats. High content screening, while rich with imaging and data outputs, has traditionally been very slow requiring hours to read all wells in 3D even in low density microplates. In this study, we demonstrate a high-content imaging workflow for the acquisition of 3D spheroid data in 1536-well microplates using the Araceli Endeavor® imaging platform. Here, we will show preliminary studies across multiple cancer cell lines demonstrating their differences in the 3D formation using 1536-well cell repellent assay plates imaged over time using brightfield microscopy to capture spheroid formation and growth behavior, at scale. This work focuses on imaging strategies and workflow considerations that enable rapid, consistent, plate-wide data acquisition in high-density formats while minimizing acquisition complexity and imaging time. The approach supports longitudinal data collection across large numbers of wells, creating a foundation for downstream quantitative analysis of spheroid morphology and growth in ultra-high-throughput screening contexts. We discuss strategies for efficiently monitoring spheroid growth in line with imaging, with results optimized to produce actionable data. Ultimately, these tools will allow monitoring 3D growth overtime, parallel formation, size monitoring and viability assessment in a highly consistent and ultra-fast manner. Together, these results highlight how high-content imaging workflows can be adapted to support scalable 3D screening, enabling broader adoption of 3D cell-based assays and more efficient experimental iteration during early-stages of drug discovery.
OPENTRONS - The New Throughput: How Adaptive Automation Is Accelerating DNA Synthesis, Molecular Diagnostics and Drug Discovery
Open to view video. | Closed captions available
Open to view video. | Closed captions available
“High throughput” used to mean monolithic, closed automation systems: powerful but rigid, designed for fixed workflows and consistent sample volumes. But today’s scientific landscape looks very different. Advances in AI, explosive computational capacity, faster and more economical chemistries, and data-rich community initiatives like biobanks are not only increasing the demand for throughput but also redefining it. These forces are driving the need for a new kind of automation: systems that are not just fast, but flexible, modular, and adaptive, capable of evolving with new methods, new assays, and new scales of discovery.
This talk explores the new throughput: automation that enables labs to scale dynamically, integrate diverse workflows, and accelerate innovation without sacrificing precision or usability.
We’ll share three use cases from teams pushing the boundaries of scale and adaptability in very different ways:
Madeline Wolf, Instance Bio – leveraging AI-driven, massively parallel DNA synthesis to generate unbounded DNA pools at unprecedented speed, scale, and size.
Arun Timmaraju, Interpace Diagnostics – applying scalable automation to accelerate molecular diagnostics workflows.
Hamza Sahil, Pfizer – demonstrating how an automated Oxford Nanopore workflow delivers rapid, scalable plasmid and cell line sequencing, with major gains in speed and efficiency.
Join us to see how advances in AI, computation, chemistry, and collaboration are converging to define the new throughput, one built not just for speed, but for agility, precision, and discovery.
AUTOMATA - The Reckoning for Legacy Labs: Evolve with AI or Become Obsolete
Open to view video. | Closed captions available
Open to view video. | Closed captions available
The lab of the future is not a room full of clever gadgets. It’s a programmable, living system where code, robots and data collaborate so aggressively that standing still becomes impossible.
GINKGO BIOWORKS - Designing, Deploying, and Scaling Autonomous Labs with PNNL and Open AI
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Autonomous labs are rapidly moving from concept to operational reality, but many organizations still face practical questions about how to deploy, scale, and extract real value from these systems. This lunchtime tutorial, hosted by Ginkgo Bioworks, focuses on the applied, real-world implementation of autonomous labs—drawing directly from active projects with OpenAI and Pacific Northwest National Laboratory (PNNL).
Ginkgo's collaboration with OpenAI brings together world-class natural language models (GPT-5) with RAC automation to reduce the reaction costs of cell-free protein synthesis, surpassing current state of the art and paving the way for use of autonomous labs in protein design and engineering. In parallel, the Department of Energy commissioned two platforms, the Anaerobic Microbial Phenotyping Platform (AMP2) and the Microbial Molecular Phenotyping Capability (M2PC) to enable national-lab scale automation for R&D in microbial phenotyping that are able to operate in conjunction with autonomous loop experimentation tools and push the boundaries of AI in U.S. science as part of the Genesis Mission. Contracts to design with PNNL researchers and then build both platforms were competitively awarded to Ginkgo.
SIMPLICIS - Modernizing Compound Management Workflows at Neurocrine: From Powders to Assay Ready Plates using Simplicis Software Platform and Ledger(TM) Acoustic
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Modernizing acoustic-ready plate production has become essential for laboratories that depend on rapid experiment turnaround times.
Legacy systems often struggle with slow data processing and rigid workflows, creating delays that cascade through biology and research teams operating on hour-level timelines.
Neurocrine Biosciences confronted this challenge by integrating Ledger™ and Ledger™ Acoustic to automate, streamline, and dramatically accelerate assay-ready plate generation.
This modernization has minimized hands-on work while cutting production time by 50%, ensuring downstream experiments can proceed within the tight windows required for success.
This session will be led by Paul Anderson, Director of Enabling Technologies at Neurocrine Biosciences, who brings extensive experience across HTS, compound management, and advanced automation technologies.
Paul will share how these improvements support peptide assay-ready plate workflows today and lay the foundation for broader sample-management modernization at Neurocrine in 2026.
SCIEX - Meet the team behind the SCIEX Echo® MS+ system for drug discovery assays
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Join SCIEX for an energizing afternoon at SLAS 2026 with a special seminar featuring our product manager, product specialist, and scientists from Pfizer and BMS. Discover the latest news about the SCIEX Echo® MS+ system and ask questions to the people who developed it.
Hear firsthand from the innovators and gain exclusive insights into how the development team works with pharmaceutical companies to drive new features and innovations for efficiency, reproducibility, and scientific impact.
ABB - From Insight to Impact: AI, Robotics and the Convergence toward the Lab of the Future?
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Roundtable: From Insight to Impact: AI, Robotics and the Convergence toward the Lab of the Future
On Tuesday, February 10, from Noon to 1:15pm EST (Room 107A), ABB Robotics will host a roundtable entitled “From Insight to Impact: AI, Robotics and the Convergence toward the Lab of the Future.” The session will bring together experts from Atinary, Agilent, Mettler Toledo, Sanofi, and ABB Robotics to discuss how AI, robotics and interoperable platforms are reshaping laboratory operations.
SPLASHLAKE - Splashlake - Building universal data accessibility into your AI strategy – Integration, standardization and governance
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Everyone’s talking about AI. How will you enable unified access to the data you have, to solve your toughest problems? Challenges such as predicting formulation performance, optimizing clinical trials, or improving yield in scale-up manufacturing, all depend on a solid data foundation. How do you get your data in good shape to feed LLMs, and know that all your incoming data is automatically adding value to your datasets? This presentation will explore how to ensure trust in data through scalable, whole-lab connectivity of instruments and software. We will look at leveraging all scientific data sources from a single location, and securing vendor agnostic and future-proofed data through machine- and human- readable data standards. We will discuss the application of multi-modal data (including files, time-series, chemical structures, and more) alongside metadata, to create a rich, fully configurable data catalog. We'll wrap up by seeing how we can generate value using LLMs, without the need to train custom models.